Breaking News
January 19, 2019 - New Leash on Life? Staying Slim Keeps Pooches Happy, Healthy
January 19, 2019 - Men and women remember pain differently
January 19, 2019 - Rising air pollution linked with increased ER visits for breathing problems
January 19, 2019 - Study uses local data to model food consumption patterns among Seattle residents
January 19, 2019 - The brain’s cerebellum plays role in controlling reward and social behaviors, study shows
January 19, 2019 - Relationship between nurse work environment and patient safety
January 19, 2019 - Pioneering surgery restores movement to children paralyzed by acute flaccid myelitis
January 19, 2019 - Genetic variants linked with risk tolerance and risky behaviors
January 19, 2019 - New research provides better understanding of our early human ancestors
January 19, 2019 - First-ever tailored reporting guidance to improve patient care and outcomes
January 19, 2019 - 4.6 percent of Massachusetts residents have opioid use disorder
January 19, 2019 - New study suggests vital exhaustion as risk factor for dementia
January 19, 2019 - New antibiotic discovery heralds breakthrough in the fight against drug-resistant bacteria
January 19, 2019 - Ural Federal University scientists synthesize a group of multi-purpose fluorophores
January 19, 2019 - Researchers identify new therapeutic target in the fight against chronic liver diseases
January 19, 2019 - Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs
January 19, 2019 - FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
January 19, 2019 - Tobacco use linked with higher use of opioids and sedatives
January 19, 2019 - Study delves deeper into developmental dyslexia
January 19, 2019 - Anti-vaccination movement one of the top health threats in 2019 says WHO
January 19, 2019 - Newly developed risk score more effective at identifying type 1 diabetes
January 19, 2019 - Highly effective protocol to prepare cannabis samples for THC/CBD analysis
January 19, 2019 - Prinston Pharmaceutical Inc. Issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodiethylamine (NDEA) in the Products
January 19, 2019 - How does solid stress from brain tumors cause neuronal loss, neurologic dysfunction?
January 19, 2019 - $14.7 million partnership to supercharge vaccine development
January 19, 2019 - Ian Fotheringham receives Charles Tennant Memorial Lecture award
January 19, 2019 - Brain vital signs detect neurophysiological impairments in players with concussions
January 19, 2019 - Lack of job and poor housing conditions increased likelihood of people attending A&E
January 19, 2019 - Novel targeted drug delivery system improves conventional cancer treatments
January 19, 2019 - Rutgers study finds gene responsible for spread of prostate cancer
January 19, 2019 - Complications Higher Than Expected for Invasive Lung Tests
January 19, 2019 - 3-D printed implant promotes nerve cell growth to treat spinal cord injury
January 19, 2019 - Automated texts lead to improved outcomes after total knee or hip replacement surgery
January 19, 2019 - Poor cardiorespiratory fitness could increase risk of future heart attack, finds new study
January 19, 2019 - Drinking soft drinks while exercising in hot weather may increase risk of kidney disease
January 19, 2019 - Formlabs 3D prints anatomical models
January 19, 2019 - Heart-Healthy Living Also Wards Off Type 2 Diabetes
January 19, 2019 - Teaching Kids to Be Smart About Social Media (for Parents)
January 19, 2019 - Metabolite produced by gut microbiota from pomegranates reduces inflammatory bowel disease
January 19, 2019 - Researchers examine how spray from showers and toilets expose us to disease causing bacteria
January 19, 2019 - Behavioral experiments confirm that additional neurons improve brain function
January 19, 2019 - New study compares performance of real-time infectious disease forecasting models
January 19, 2019 - Obesity can be risk factor for developing renal cell carcinoma, confirms study
January 19, 2019 - New regulation designs on cigarette packs direct smokers’ attention to health warnings
January 19, 2019 - QIAGEN receives first companion diagnostic approval in Japan
January 19, 2019 - Study explores role of Dunning-Kruger effect in anti-vaccine attitudes
January 19, 2019 - Newly identified subset of immune cells may be key to fighting chronic inflammation
January 19, 2019 - New immune response regulators discovered
January 18, 2019 - Poor blood oxygenation during sleep predicts chance of heart-related death
January 18, 2019 - First international consensus on the diagnosis and management of fibromuscular dysplasia
January 18, 2019 - Rapid resistance gene sequencing technology can hasten identification of antibiotic-resistant bacteria
January 18, 2019 - Researchers develop artificial enzymatic pathway for synthesizing isoprenoids in E. coli
January 18, 2019 - Scientists advise caution in immunotherapy research
January 18, 2019 - How children across the world develop language
January 18, 2019 - Columbia Medical Student Receives McDonogh Scholarship
January 18, 2019 - Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
January 18, 2019 - Plant based diet could be the best option for the planet says commission
January 18, 2019 - New conservation practice could reduce nitrogen from agricultural drainage, study shows
January 18, 2019 - UIC researchers receive $1.7 million NCI grant to study Southeast Asian fruit
January 18, 2019 - New study determines the fate of DNA derived from genetically modified food
January 18, 2019 - Scientists develop new gene therapy that prevents axon destruction in mice
January 18, 2019 - Study finds critically low HPV vaccination rates among younger adolescents in the U.S.
January 18, 2019 - Brain cells involved in memory play key role in reducing future eating behavior
January 18, 2019 - Risk for Conversion of MS Varies With Different Therapies
January 18, 2019 - Investigational cream may help patients with inflammatory skin disease
January 18, 2019 - Medical school news office receives six writing awards | News Center
January 18, 2019 - County By County, Researchers Link Opioid Deaths To Drugmakers’ Marketing
January 18, 2019 - Research reveals risk for developing more than one mental health disorder
January 18, 2019 - Scientists discover a dramatic pattern of bone growth in female mice
January 18, 2019 - Study finds link between lengthy periods of undisturbed maternal sleep and stillbirths
January 18, 2019 - New nuclear medicine method could improve detection of primary and metastatic melanoma
January 18, 2019 - Combination therapy shows high efficacy in treating people with leishmaniasis and HIV
January 18, 2019 - Health Tip: Don’t Ignore Changes in Skin Color
January 18, 2019 - Dietary Recommendations for Healthy Children
January 18, 2019 - Eliminating the latent reservoir of HIV
January 18, 2019 - Pain From The Government Shutdown Spreads. This Time It’s Food Stamps
January 18, 2019 - Newly discovered regulatory mechanism helps control fat metabolism
January 18, 2019 - New rapid blood tests could speed up TB diagnosis, save the NHS money
January 18, 2019 - Researchers develop intelligent system for ‘tuning’ powered prosthetic knees
January 18, 2019 - Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma
G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer

G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer

image_pdfDownload PDFimage_print

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced data from new analyses of its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for the treatment of first-line small cell lung cancer (SCLC). The analyses demonstrated clinically meaningful improvements for neutrophil, red blood cell (RBC) and lymphocyte measures in patients treated with trilaciclib compared to placebo. With regard to lymphocytes, trilaciclib preserved or improved B cell and T cell subset counts, including activated CD8+ cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios in peripheral blood compared to placebo. These data were presented in two separate posters at the European Society for Medical Oncology (ESMO) 2018 Congress, being held in Munich, Germany.

“The totality of these favorable data highlight the unique, multi-lineage myelopreservation potential of trilaciclib. Trilaciclib demonstrated improvement in multiple hematological endpoints, including neutrophils, red blood cells and lymphocytes, which may improve outcomes for patients receiving chemotherapy. Trilaciclib may also enhance immune system function, potentiating the efficacy of chemotherapy/checkpoint combinations,” said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. “Chemotherapy remains a cornerstone of cancer treatment, and emerging data support the use of chemotherapy/checkpoint combinations in an increasing number of indications. Trilaciclib may play an important role in multiple chemotherapy treatment regimens. In addition to the data presented at ESMO, we expect to report findings from three other randomized Phase 2 clinical trials combining trilaciclib with chemotherapy and chemotherapy/checkpoint regimens by the end of the year.”

The company reported topline data from this trial in March 2018 showing robust myelopreservation benefits of trilaciclib. Consistent with previously reported results, new analyses demonstrated that trilaciclib reduced clinically relevant consequences of chemotherapy-induced myelosuppression versus placebo. Overall, there were fewer ≥ Grade 3 treatment emergent adverse events (TEAEs) with trilaciclib compared to placebo (28.9 percent versus 75.7 percent), mostly due to lower number of ≥ Grade 3 hematologic TEAEs (23.7 percent versus 73.0 percent).

Myelopreservation Findings: Neutrophils and Red Blood Cells

  • Neutrophils: consistent with previously reported data, treatment with trilaciclib compared to placebo reduced rates of Grade 4 absolute neutrophil count (ANC) (5.3 percent versus 43.2 percent; p=0.0001), Grade 4 ANC in the first chemotherapy cycle (2.6 percent versus 35.1 percent; p=0.0003) and granulocyte-colony stimulating factor (G-CSF) administration (10.5 percent versus 64.9 percent; p
  • RBCs: new analyses of the trial data showed that treatment with trilaciclib compared to placebo reduced rates of RBC transfusions (10.5 percent versus 24.3 percent; p=0.1109), transfusions on or after five weeks on study (5.7 percent versus 21.6 percent; p=0.0615) and Grade 3/4 hemoglobin values (10.5 percent versus 18.9 percent).

Myelopreservation Findings: Lymphocyte/Immune System Function
Analyses of absolute numbers and percentages of immune subsets were conducted by flow cytometry using peripheral blood samples.

Patients who received trilaciclib demonstrated faster recovery of lymphocytes following chemotherapy compared to those who received placebo. Analyses of lymphocyte subpopulations showed that the addition of trilaciclib to chemotherapy preserved or increased B and T lymphocyte counts, increased the total number of CD8+ T cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios compared to placebo. Collectively, these data support that trilaciclib has the potential to preserve multiple immune system components and enhance CD8+ cell function. In preclinical studies, the presence of activated CD8+ cells and higher activated CD8+/regulatory T cell ratio have been shown to improve the efficacy of checkpoint inhibitors.

Anti-Tumor Findings

In this trial, measures of anti-tumor efficacy trended in favor of trilaciclib without reaching statistical significance. Overall response rate (complete response + partial response) for the response-evaluable population as assessed by investigators was 66.7 percent for trilaciclib versus 56.8 percent for placebo and median duration of response was 5.7 months for trilaciclib versus 5.4 months for placebo. Median progression free survival was 6.1 months for trilaciclib versus 5.0 months for placebo (hazard ratio 0.68; p=0.1286) and median overall survival (OS) was 10.9 months for trilaciclib versus 10.6 months for placebo (hazard ratio 0.86; p=0.5948). OS data are still immature; the company plans to provide an update in 2019. A greater percentage of patients receiving trilaciclib went on to additional lines of treatment compared to those receiving placebo (44.7 percent versus 40.5 percent).

Safety Findings

Consistent with previously reported results, trilaciclib was well tolerated. TEAEs more commonly reported in the trilaciclib arm compared to placebo included fatigue, nausea, upper abdominal pain, and headache; the majority of these events were reported as Grade 1/2 in severity. There were no trilaciclib- related ≥ Grade 3 TEAEs reported.

Trial Design

This double-blind, placebo-controlled Phase 2 trial enrolled patients with a confirmed diagnosis of extensive-stage SCLC. The trial randomized 77 treatment-naïve patients in a 1:1 ratio, and 75 received trilaciclib or placebo administered intravenously prior to chemotherapy. Consistent with standard of care, patients generally received up to six cycles of chemotherapy. Patients in both arms of the trial were able to receive standard supportive care as recommended by the trial investigator. Growth factors, including G-CSF and erythropoietin, and transfusion support were available to all patients. Baseline demographics and disease characteristics were generally well balanced between the two arms. The statistical analysis plan prospectively defined several clinically relevant endpoints.

About Trilaciclib

Trilaciclib is a first-in-class myelopreservation therapy designed to preserve hematopoietic stem and progenitor cell function, as well as immune system function, during chemotherapy. Trilaciclib is a short-acting intravenous CDK4/6 inhibitor administered prior to chemotherapy and has the potential to significantly improve treatment outcomes.

Trilaciclib is being evaluated in four randomized Phase 2 clinical trials. In March 2018, G1 announced positive Phase 2 data showing myelopreservation benefits in newly diagnosed, treatment-naive small cell lung cancer (SCLC) patients (NCT02499770). Additional results from this trial were reported at the European Society for Medical Oncology (ESMO) 2018 Congress in October 2018. The company plans to report topline data from two other randomized Phase 2 SCLC trials in the fourth quarter of 2018: a trial in combination with chemotherapy and Tecentriq® in first-line SCLC (NCT03041311) and a trial in combination with chemotherapy in previously treated SCLC (NCT02514447). Preliminary data from a trial in combination with chemotherapy in triple-negative breast cancer (NCT02978716) will be reported in a Spotlight Session at the San Antonio Breast Cancer Symposium on December 5, 2018.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, trilaciclib, lerociclib and G1T48, that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, lerociclib and G1T48, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein and include, but are not limited to, G1 Therapeutics’ ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; G1 Therapeutics’ initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; G1 Therapeutics’ development of a CDK4/6 inhibitor to reduce chemotherapy-induced myelosuppression is novel, unproven and rapidly evolving and may never lead to a marketable product; and market conditions. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Source: G1 Therapeutics

Posted: October 2018

About author

Related Articles